title: Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments.
abstract: Nanoparticles occur naturally as part of repetitive molecular structures forming virus-like particles (VLPs). VLPs are powerful immune activators. Specifically, VLP can elicit a direct activation of B lymphocytes to trigger production of antibodies targeted at molecules chemically linked to the VLP. We here review recent data from genetics research, large-scale genomic sequencing, as well as clinical trials which suggest that a VLP-based vaccine against the signaling molecule IL-17 will be safe and effective in the common skin disease psoriasis, as well as other conditions. Active vaccination against IL-17 is capable of replacing the costly manufacture of antibodies currently in clinical use with huge implications for treatment availability and health economics.
authors.affiliation: College of Medicine, Dentistry, & Nursing, University of Dundee, Dundee, DD1 9SY, UK.
authors.forename: John
authors.initials: J
authors.lastname: Foerster
authors.forename: Martin
authors.initials: M
authors.lastname: Bachman
mesh_terms: D000818:Animals; D006801:Humans; D007116:Immunization, Passive; D020381:Interleukin-17 / Q000276:immunology*; D053758:Nanoparticles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D011565:Psoriasis / Q000276:immunology / Q000517:prevention & control; D014611:Vaccination; D058425:Vaccines, Virus-Like Particle / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: C508717:IL17A protein, human; D020381:Interleukin-17; D058425:Vaccines, Virus-Like Particle
keywords: IL-17; psoriasis; vaccine; virus-like particle